110 related articles for article (PubMed ID: 32545760)
1. Evaluating the Therapeutic Efficacy of Mono- and Bivalent Affibody-Based Fusion Proteins Targeting HER3 in a Pancreatic Cancer Xenograft Model.
Leitao CD; Rinne SS; Altai M; Vorontsova O; Dunås F; Jonasson P; Tolmachev V; Löfblom J; Ståhl S; Orlova A
Pharmaceutics; 2020 Jun; 12(6):. PubMed ID: 32545760
[TBL] [Abstract][Full Text] [Related]
2. Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic Constructs.
Altai M; Leitao CD; Rinne SS; Vorobyeva A; Atterby C; Ståhl S; Tolmachev V; Löfblom J; Orlova A
Cells; 2018 Oct; 7(10):. PubMed ID: 30314301
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the Therapeutic Potential of a HER3-Binding Affibody Construct TAM-HER3 in Comparison with a Monoclonal Antibody, Seribantumab.
Orlova A; Bass TZ; Rinne SS; Leitao CD; Rosestedt M; Atterby C; Gudmundsdotter L; Frejd FY; Löfblom J; Tolmachev V; Ståhl S
Mol Pharm; 2018 Aug; 15(8):3394-3403. PubMed ID: 29995421
[TBL] [Abstract][Full Text] [Related]
4. In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct.
Bass TZ; Rosestedt M; Mitran B; Frejd FY; Löfblom J; Tolmachev V; Ståhl S; Orlova A
Sci Rep; 2017 Feb; 7():43118. PubMed ID: 28230065
[TBL] [Abstract][Full Text] [Related]
5. Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of
Dahlsson Leitao C; Rinne SS; Mitran B; Vorobyeva A; Andersson KG; Tolmachev V; Ståhl S; Löfblom J; Orlova A
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30832342
[TBL] [Abstract][Full Text] [Related]
6. HER3 PET Imaging:
Rinne SS; Leitao CD; Abouzayed A; Vorobyeva A; Tolmachev V; Ståhl S; Löfblom J; Orlova A
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638277
[TBL] [Abstract][Full Text] [Related]
7. Increase in negative charge of
Rinne SS; Dahlsson Leitao C; Gentry J; Mitran B; Abouzayed A; Tolmachev V; Ståhl S; Löfblom J; Orlova A
Sci Rep; 2019 Nov; 9(1):17710. PubMed ID: 31776413
[TBL] [Abstract][Full Text] [Related]
8. Affibody-mediated PET imaging of HER3 expression in malignant tumours.
Rosestedt M; Andersson KG; Mitran B; Tolmachev V; Löfblom J; Orlova A; Ståhl S
Sci Rep; 2015 Oct; 5():15226. PubMed ID: 26477646
[TBL] [Abstract][Full Text] [Related]
9. Comparative evaluation of 111In-labeled NOTA‑conjugated affibody molecules for visualization of HER3 expression in malignant tumors.
Andersson KG; Rosestedt M; Varasteh Z; Malm M; Sandström M; Tolmachev V; Löfblom J; Ståhl S; Orlova A
Oncol Rep; 2015 Aug; 34(2):1042-8. PubMed ID: 26059265
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a radiocobalt-labelled affibody molecule for imaging of human epidermal growth factor receptor 3 expression.
Rosestedt M; Andersson KG; Mitran B; Rinne SS; Tolmachev V; Löfblom J; Orlova A; Ståhl S
Int J Oncol; 2017 Dec; 51(6):1765-1774. PubMed ID: 29039474
[TBL] [Abstract][Full Text] [Related]
11. Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake.
Rosestedt M; Andersson KG; Rinne SS; Leitao CD; Mitran B; Vorobyeva A; Ståhl S; Löfblom J; Tolmachev V; Orlova A
Sci Rep; 2019 May; 9(1):6779. PubMed ID: 31043683
[TBL] [Abstract][Full Text] [Related]
12. Optimization of HER3 expression imaging using affibody molecules: Influence of chelator for labeling with indium-111.
Rinne SS; Leitao CD; Mitran B; Bass TZ; Andersson KG; Tolmachev V; Ståhl S; Löfblom J; Orlova A
Sci Rep; 2019 Jan; 9(1):655. PubMed ID: 30679757
[TBL] [Abstract][Full Text] [Related]
13. Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification.
Malm M; Kronqvist N; Lindberg H; Gudmundsdotter L; Bass T; Frejd FY; Höidén-Guthenberg I; Varasteh Z; Orlova A; Tolmachev V; Ståhl S; Löfblom J
PLoS One; 2013; 8(5):e62791. PubMed ID: 23675426
[TBL] [Abstract][Full Text] [Related]
14. Influence of Residualizing Properties of the Radiolabel on Radionuclide Molecular Imaging of HER3 Using Affibody Molecules.
Rinne SS; Xu T; Dahlsson Leitao C; Ståhl S; Löfblom J; Orlova A; Tolmachev V; Vorobyeva A
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32075258
[TBL] [Abstract][Full Text] [Related]
15. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
Orlova A; Jonsson A; Rosik D; Lundqvist H; Lindborg M; Abrahmsen L; Ekblad C; Frejd FY; Tolmachev V
J Nucl Med; 2013 Jun; 54(6):961-8. PubMed ID: 23528382
[TBL] [Abstract][Full Text] [Related]
16. Engineering of a bispecific affibody molecule towards HER2 and HER3 by addition of an albumin-binding domain allows for affinity purification and in vivo half-life extension.
Malm M; Bass T; Gudmundsdotter L; Lord M; Frejd FY; Ståhl S; Löfblom J
Biotechnol J; 2014 Sep; 9(9):1215-22. PubMed ID: 24678002
[TBL] [Abstract][Full Text] [Related]
17. PET Imaging of HER2-Positive Tumors with Cu-64-Labeled Affibody Molecules.
Qi S; Hoppmann S; Xu Y; Cheng Z
Mol Imaging Biol; 2019 Oct; 21(5):907-916. PubMed ID: 30617730
[TBL] [Abstract][Full Text] [Related]
18. Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules.
Rinne SS; Yin W; Borras AM; Abouzayed A; Leitao CD; Vorobyeva A; Löfblom J; Ståhl S; Orlova A; Gräslund T
Biomedicines; 2022 May; 10(6):. PubMed ID: 35740315
[TBL] [Abstract][Full Text] [Related]
19. Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer.
Heskamp S; Laverman P; Rosik D; Boschetti F; van der Graaf WT; Oyen WJ; van Laarhoven HW; Tolmachev V; Boerman OC
J Nucl Med; 2012 Jan; 53(1):146-53. PubMed ID: 22173842
[TBL] [Abstract][Full Text] [Related]
20. Influence of nuclides and chelators on imaging using affibody molecules: comparative evaluation of recombinant affibody molecules site-specifically labeled with ⁶⁸Ga and ¹¹¹In via maleimido derivatives of DOTA and NODAGA.
Altai M; Strand J; Rosik D; Selvaraju RK; Eriksson Karlström A; Orlova A; Tolmachev V
Bioconjug Chem; 2013 Jun; 24(6):1102-9. PubMed ID: 23705574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
